Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as
remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
The investigators will utilize electrophysiologic techniques and magnetic resonance imaging
to quantify the effect of treatment in 50 women over the course of 6 months.
Participants may remain on their standard disease modifying treatment during the course of
the trial but may not concurrently participate in any other investigational new drug research
study.
Phase:
Phase 2
Details
Lead Sponsor:
Riley Bove, MD University of California, San Francisco